Shots: The P-III MYSTIC Trial involves assessing of Imfinzi (durvalumab) as a monothx or Imfinzi plus tremelimumab vs SoC Pt-based CT in patients with EGFR and anaplastic lymphoma kinase (ALK) […]readmore
Tags : P-III
Shots: The filling is based on the results of P-III IMpassion130 study, assessing Tecentriq + Abraxane vs PBO + Abraxane in 902 patients with 1L unresectable LA/M TNBC in ratio […]readmore
Shots: Emgality’s approval is based on two P-III trials (N=425) (EVOLVE-1 and EVOLVE-2) and one P-III REGAIN trial (N=450) administering once monthly PBO vs Emgality 120 mg after an initial […]readmore
Shots: Approval of Cabometyx (cabozantinib) is based on results of the P-III METEOR trial assessing Cabometyx vs everolimus for advanced (RCC) previously received vascular endothelial growth factor (VEGF) targeted therapy, […]readmore
Shots: The BORA P-III trial involves assessing of Fasenra (benralizumab) enrolling patients in ratio (1:1) who have completed one of the two SIROCCO or CALIMA P-III trials, administering Fasenra 30 […]readmore
Shots: Results: ESTEEM 1, 2: NAPSI@32wk (31.3% vs 15.5), DLQI @16wks. (28.7% vs 8.1%); UNVEIL: NAPSI@32wks. (36.2% vs 37.2%), DLQI@16wks. (23.7% vs 10.6%) Though, Post-hoc analysis revealed that OTEZLA was […]readmore